Trial Profile
Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 03 Dec 2015 New trial record